Business Overview: Alphatec Holdings, Inc. (NASDAQ: ATEC)

---

Executive Summary

Alphatec Holdings, Inc. ("ATEC") is a medical device company singularly focused on the spine surgery market. Headquartered in Carlsbad, California, Alphatec was refounded around a strategy of "transforming spine surgery" by combining implants, enabling technologies (imaging, navigation, robotics), and a proceduralized approach that standardizes how surgeons perform complex spinal fusion procedures. Unlike large diversified medtech conglomerates, ATEC does one thing — spine — and has used that focus to take share from larger, more distracted competitors, growing revenue from roughly $190 million in 2019 to well over $550 million in recent years.

---

1. Core Business Model & How They Work

Alphatec generates revenue almost entirely from the sale of spinal implants (screws, rods, interbody cages) and the surgical instrument sets, imaging, and navigation platforms used to place them. Its economic engine runs on a "razor/razorblade"-adjacent model common in orthopedic devices:

[ Capital Placement of Imaging/Nav/Robotics Systems ] ➡️ [ Surgeon Training on Proprietary Technique (e.g., PTP lateral fusion) ] ➡️ [ Recurring Implant & Disposable Set Sales per Procedure ] ➡️ [ Distributor/Direct Sales Force Expansion ]

Key Operational Drivers

1. Full-Body Imaging & Navigation Ecosystem: ATEC's acquisition of EOS imaging gave it a proprietary low-dose, full-body 3D imaging platform that integrates with its navigation and surgical planning software, creating a closed-loop ecosystem competitors must match feature-by-feature.
2. Proceduralized Solutions: Rather than selling a-la-carte implants, ATEC packages a standardized surgical technique (e.g., its Prone Transpsoas, or "PTP," approach to lateral lumbar interbody fusion) with the instrumentation needed to execute it, reducing variability and surgeon learning curves.
3. Aggressive Commercial Investment: ATEC has prioritized building a large, well-incentivized distributor and direct sales network, funding this via convertible debt and equity even at the cost of near-term GAAP profitability.
4. New Product Cadence: A steady stream of FDA 510(k) clearances for implants, expandable cages, and robotics/navigation upgrades keeps the portfolio current against larger rivals' R&D budgets.

---

2. Product Portfolio & Revenue Drivers

---

3. Competitive Landscape

                     High Surgical/Tech Sophistication
                                   │
                Globus Medical ●   │   ● ATEC
             (scale + robotics)    │  (proceduralized focus)
     ─────────────────────────────┼─────────────────────────────
      Broad Portfolio             │            Spine-Only Focus
             Medtronic Spine ●    │   ● SI-Bone (SI joint niche)
             Stryker Spine  ●     │   ● Zimmer Biomet Spine
                                   │
                        Lower Surgical/Tech Sophistication

Competitors

• Medtronic Spine: The largest player by revenue, with deep hospital relationships and its own navigation/robotics (Mazor); ATEC competes by out-innovating on procedural workflow rather than matching Medtronic's scale.
• Globus Medical (including legacy NuVasive): Following the 2023 Globus–NuVasive merger, this is ATEC's closest scale peer and most direct competitive threat, with a similarly broad implant-plus-enabling-technology strategy.
• Stryker Spine and Zimmer Biomet Spine: Diversified orthopedic majors for whom spine is one of several business lines; ATEC's exclusive focus lets it move faster on spine-specific innovation.
• SI-Bone: A smaller, more specialized competitor in the adjacent sacroiliac joint fusion niche.

---

4. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Proprietary EOS imaging plus navigation creates a differentiated, hard-to-replicate procedural ecosystem.
• Pure-play spine focus concentrates R&D and sales-force attention that diversified competitors must split across many device categories.
• A large, growing base of surgeons trained on ATEC-specific techniques (like PTP) creates switching friction once adopted.
• Consistent above-market revenue growth has built commercial momentum and shelf-space with hospital systems.

Strategic Risks & Vulnerabilities

1. Persistent GAAP losses: Heavy sales-force and R&D investment has kept the company unprofitable on a GAAP basis even as revenue scales. Mitigation: management targets positive adjusted EBITDA and free cash flow inflection as the sales force matures.
2. Capital structure/leverage: Growth has been funded substantially with convertible notes, creating dilution and refinancing risk. Mitigation: continued revenue growth and margin expansion to delever over time.
3. Consolidation among rivals: The Globus–NuVasive combination creates a larger, better-capitalized direct competitor. Mitigation: continued focus on differentiated technology and surgeon relationships rather than scale competition.
4. Reimbursement and hospital cost pressure: Hospitals and GPOs continually push back on implant pricing. Mitigation: bundling implants with proprietary imaging/navigation to justify premium pricing.

---

5. Financial Overview

---

6. Summary Conclusion

Alphatec has proven that a pure-play, technologically differentiated challenger can consistently take share from far larger spine competitors by out-innovating on procedural workflow rather than competing purely on portfolio breadth or price. Its EOS imaging and PTP procedural ecosystem give surgeons real reasons to switch, and revenue growth has remained well above the broader spine market for several years running.

The central question for ATEC is one of financial maturation: can the company convert its commercial momentum into sustained GAAP profitability and free cash flow before its convertible debt load and continued need for growth capital become a constraint, particularly as a larger, newly-merged Globus-NuVasive competes more aggressively for the same surgeons and hospital accounts.